Announcement • Oct 29
Ascendis Health Limited, Annual General Meeting, Nov 21, 2025 Ascendis Health Limited, Annual General Meeting, Nov 21, 2025. Announcement • Sep 17
Ascendis Plans to Delist from JSE Satisfy Market Ascendis Health Limited plans to delist from the JSE, buying out shareholders with "internally generated resources", subject to an independent assessment of the offer, sending the stock soaring as much as 13.4% on September 12, 2025. The health and wellness group said on September 12, 2025 that the board had initiated a process for a potential delisting, together with a conditional offer to repurchase shares at 97 cents cash each. The shares were at 90 cents by the close of trading on September 12, 2025, having pared their gains to 9.8%, though they are down 10% in the year to date. The company's board said in the statement that it believed delisting is the best option available to unlock further value for the company and enable it to pursue initiatives such as acquisitions and disposals more effectively and speedily. The delisting is also the most effective mechanism of unlocking and returning value to Ascendis Health's shareholders, it said. The decision comes after a review of the company's options and the environment in which it operates. While the business has a strong pipeline of attractive potential transactions, the additional regulations associated with maintaining a JSE listing, particularly for a smaller cap company, impedes agility and slows the ability to acquire new businesses, Ascendis said. "The listed environment, while valuable in many respects for larger companies, has imposed regulatory and cost constraints that limit our ability to act on transactions that could unlock meaningful value," said CEO Carl Neethling." As a smaller company, we continue to endure extreme scrutiny and we believe that operating outside the listed environment will provide us with greater flexibility to pursue growth opportunities and ultimately deliver enhanced value for all our stakeholders."The vast majority of shareholders have indicated their support, Ascendis said. Announcement • Mar 24
Ascendis Health Limited to Report First Half, 2025 Results on Mar 27, 2025 Ascendis Health Limited announced that they will report first half, 2025 results on Mar 27, 2025 Announcement • Nov 30
Ascendis Health Limited Announces Appointment of Amaresh Chetty and Hendrik Ackermann Nolte as Member of the Audit and Risk Committee Ascendis Health Limited announced that the AGM held on 29 November 2024, Appointment of Amaresh Chetty as a member of the audit and risk committee; Appointment of Hendrik Ackermann Nolte as a member of the audit and risk committee. Announcement • Nov 01
Ascendis Health Limited, Annual General Meeting, Nov 29, 2024 Ascendis Health Limited, Annual General Meeting, Nov 29, 2024. Announcement • Sep 20
An undisclosed buyer acquired an unknown minority stake in Ascendis Health Limited (JSE:ASC) from Alpvest Equities Proprietary Limited. An undisclosed buyer acquired an unknown minority stake in Ascendis Health Limited (JSE:ASC) from Alpvest Equities Proprietary Limited on September 19, 2024.
An undisclosed buyer completed the acquisition of an unknown minority stake in Ascendis Health Limited (JSE:ASC) from Alpvest Equities Proprietary Limited on September 19, 2024. Announcement • Aug 30
Ascendis Health Limited to Report Fiscal Year 2024 Results on Sep 03, 2024 Ascendis Health Limited announced that they will report fiscal year 2024 results on Sep 03, 2024 Announcement • Mar 27
Ascendis Health Limited to Report First Half, 2024 Results on Mar 28, 2024 Ascendis Health Limited announced that they will report first half, 2024 results on Mar 28, 2024 Announcement • Nov 30
Ascendis Health Limited Announces Lawrence Mulaudzi Not Available for Re-Election as Director Ascendis Health Limited at the annual general meeting held on 30 November 2023 resolution has been withdrawn as Mr. Lawrence Mulaudzi did not make himself available for re-election as a director. Mr. Lawrence Mulaudzi is no longer an independent non-executive director of the Company, with effect from 30 November 2023. Announcement • Nov 01
Ascendis Health Limited, Annual General Meeting, Nov 30, 2023 Ascendis Health Limited, Annual General Meeting, Nov 30, 2023, at 11:00 South Africa Standard Time. Agenda: To consider appointment of auditors; to consider re-election of retiring non-executive director Mr. Amaresh Chetty; to consider re-election of retiring non-executive director Mr. Lawrence Mulaudzi; to consider appointment of members of the Audit and risk committee; to consider general authority to issue shares for cash; to consider Endorsement of Company's Remuneration policy; to consider Endorsement of Company's Remuneration implementation; to consider general authority to repurchase shares; and to consider any other matters. Announcement • Sep 29
Ascendis Health To Delist from JSE, Upon Deal Goes Through Ascendis Health could soon disappear from the JSE, 10 years after the healthcare start-up debuted on the public platform amid fanfare before descending into a nightmare for the shareholders. Ascendis, which owns vitamin brands and medical devices, said on September 27, 2023 that it had initiated a process to look into the potential delisting "as the next step in its strategy to unlock value and return capital to Ascendis shareholders". The early discussions are being conducted with a consortium led by ACN Capital, a private equity outfit controlled by acting CEO Carl Neethling. Announcement • Sep 28
Ascendis Health Limited Appoints Joseph Fine as Company Secretary Ascendis Health Limited advised that Mr. Joseph Fine ("Fine") has been appointed as company secretary of the Company with effect from 29 September 2023. As Head of Legal of the Company, Mr. Fine has performed the function of company secretary following the resignation of the previous company secretary. The board of the Company is satisfied with the performance, experience and expertise of Mr. Fine as company secretary and has therefore appointed him in this role. Board Change • Sep 21
High number of new and inexperienced directors There are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. No experienced directors. No highly experienced directors. Non-Independent Non-Executive Director Shumani Mulaudzi is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Announcement • Sep 30
Ascendis Health Limited, Annual General Meeting, Nov 30, 2022 Ascendis Health Limited, Annual General Meeting, Nov 30, 2022, at 10:00 South Africa Standard Time. Agenda: To consider re-appointment of auditors; to consider re-election of retiring non-executive directors of the Company retiring by rotation; to consider appointment of audit and risk committee; to consider endorsement of Ascendis Health Remuneration Policy; to consider endorsement of Ascendis Health Remuneration Implementation Report; to approve non-executive directors' remuneration; to approve financial assistance in terms of section 44 of the Act; to approve financial assistance in terms of section 45 of the Act; and to discuss other matters. Announcement • Sep 27
Ascendis Health Limited to Report Fiscal Year 2022 Results on Sep 28, 2022 Ascendis Health Limited announced that they will report fiscal year 2022 results on Sep 28, 2022 Announcement • Jun 14
Ascendis Health Limited Announces Board Changes Ascendis Health Limited announced that following the appointment of Amaresh Chetty, Bharti Harie and Carl Neethling as directors of Ascendis Health and the resignation of Gary Shayne as a director of Ascendis Health, the committees of the board of directors of Ascendis Health (the "Board") have been reconstituted to comprise the following members: Audit and risk committee: Bharti Harie (chairman), Amaresh Chetty, Karsten Wellner and Lawrence Mulaudzi. Human capital committee: Amaresh Chetty (chairman), Bharti Harie, Harry Smit and Carl Neethling. Social, ethics and transformation committee: Amaresh Chetty (chairman), Lawrence Mulaudzi, Harry Smit, Bharti Harie and CJ Kujenga. The Board has conducted an evaluation in respect of the independence of the non-executive directors of Ascendis Health. Karsten Wellner, Lawrence Mulaudzi and Carl Neethling have been designated non-independent non-executive directors and Harry Smit, Richard Dawes, Amaresh Chetty and Bharti Harie have been designated independent non-executive directors. Announcement • Sep 24
Ascendis Considers Delisting from JSE Ascendis Health Limited said on September 20, 2021 it is seriously considering selling off all its businesses and delisting from the JSE. The option of remaining a listed group, while still being reviewed, is challenged by plans that will significantly reduce the scale of the group, Ascendis said. This restructuring plan, set to be voted on by shareholders in October 2021, entails giving up its most profitable businesses. Announcement • Jul 20
Kefolile Health Investments Pty Ltd acquired an unknown minority interest in Ascendis Health Limited (JSE:ASC) Kefolile Health Investments Pty Ltd acquired an unknown minority interest in Ascendis Health Limited (JSE:ASC) on July 19, 2021. Post completion, Kefolile Health Investments total interest in Ascendis Health is 11.71%.
Kefolile Health Investments Pty Ltd completed the acquisition of an unknown minority interest in Ascendis Health Limited (JSE:ASC) on July 19, 2021. Announcement • Jun 26
MMC International Health Holding S.L entered into sale of shares agreement to acquire Farmalider, S.A. from Ascendis Health Limited (JSE:ASC) for €5 million. MMC International Health Holding S.L entered into sale of shares agreement to acquire Farmalider, S.A. from Ascendis Health Limited (JSE:ASC) for €5 million on June 25, 2021. The consideration is paid in cash. The transaction is subject to Ascendis Health obtaining the written approval of Ascendis Health’s lenders under the existing bank facilities, of the sale and transfer of the Sale Shares contemplated by the SPA, to the extent required, the Financial Surveillance Department of the South African Reserve Bank approving the sale and transfer of the Sale Shares contemplated by the SPA and the finalisation of a licence and supply agreement between the Company and Farmalider, by no later than 2 July 2021. Ascendis Health will use the net proceeds from the Disposal to reduce the Group’s debt. The Disposal will be implemented on the Closing Date, which is expected to take place within 10 business days from the date of fulfilment of the Conditions Precedent . Announcement • May 14
The management of Respiratory Care Africa (Pty) Ltd. agreed to acquire Respiratory Care Africa (Pty) Ltd. from Ascendis Health Limited (JSE:ASC) in a management buyout transaction. The management of Respiratory Care Africa (Pty) Ltd. agreed to acquire Respiratory Care Africa (Pty) Ltd. from Ascendis Health Limited (JSE:ASC) in a management buyout transaction in February 2021. The transaction is approved by majority Lenders and board of Respiratory Care Africa (Pty) Ltd and is subject to shareholder approval. Net proceeds from the transaction will be used by Ascendis Health Limited for unsustainable capital structure and future operational liquidity requirements, whilst protecting value for all Ascendis Health Limited’s stakeholders. Rothschild & Co South Africa acted as corporate advisor and Allen & Overy (South Africa) LLP acted as legal advisor to Ascendis Health Limited. Reported Earnings • Apr 02
First half 2021 earnings released: R0.63 loss per share (vs R0.16 profit in 1H 2020) The company reported a mediocre first half result with weaker earnings and weaker control over costs, although revenues improved. First half 2021 results: Revenue: R3.98b (up 33% from 1H 2020). Net loss: R301.1m (down 493% from profit in 1H 2020). Over the last 3 years on average, the company's earnings growth rate has exceeded its share price growth rate by 3 percentage points per year. Executive Departure • Mar 15
Independent Non-Executive Director has left the company On the 11th of March, Noluyolo Jekwa's tenure as Independent Non-Executive Director ended after 2.7 years in the role. As of December 2020, Noluyolo personally held only 9.22k shares (R6.9k worth at the time). A total of 4 executives have left over the last 12 months. Announcement • Mar 06
Ascendis Health Limited Announces Resignation of Yoza Jekwa, with Effect from 11 March 2021 Ascendis Health Limited announced that Dr. Yoza Jekwa has resigned as independent non-executive director of the Company with effect from 11 March 2021 and as a result will cease to be a member of the audit and risk committee of the Company following that date. Announcement • Feb 18
Ascendis Health Limited to Report First Half, 2021 Results on Mar 31, 2021 Ascendis Health Limited announced that they will report first half, 2021 results on Mar 31, 2021 Is New 90 Day High Low • Feb 15
New 90-day low: R0.66 The company is down 6.0% from its price of R0.70 on 17 November 2020. The South African market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 12% over the same period. Announcement • Dec 02
Ascendis Health Limited Approves Board Changes Ascendis Health Limited approved the appointment of Cheryl-Jane Kujenga as an executive director, Sango Siviwe Ntsaluba as the chairman of the Audit and Risk Committee, Bharti Harie as a member of the Audit and Risk Committee, and Johannes George Sebulela as a member of the Audit and Risk Committee, at its annual general meeting of shareholders held on December 1, 2020. Is New 90 Day High Low • Nov 20
New 90-day high: R0.81 The company is up 21% from its price of R0.67 on 21 August 2020. The South African market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 1.0% over the same period. Reported Earnings • Nov 03
Full year 2020 earnings released: R1.74 loss per share The company reported a solid full year result with reduced losses and improved revenues and control over expenses. Full year 2020 results: Revenue: R6.96b (up 19% from FY 2019). Net loss: R830.8m (loss narrowed 54% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 87% per year but the company’s share price has only fallen by 68% per year, which means it has not declined as severely as earnings. Announcement • Oct 30
Ascendis Health Limited Announces the Changes to Board Committees Ascendis Health Limited announced the changes to the Social, Ethics and Transformation Committee and the Audit and Risk Committee with effect from 1 November 2020: Ms Bharti Harie will assume responsibility as the chairman of the Social, Ethics and Transformation Committee. Ms Harie will step down as the chairman of the Audit and Risk Committee but will be retained as a member of the Audit and Risk Committee; Mr. Sango Siviwe Ntsaluba will assume responsibility as the chairman of the Audit and Risk Committee; and Mr. George Sebulela will assume responsibility as a member of the Audit and Risk Committee. The Audit and Risk Committee appointments are subject to approval by the shareholders of Ascendis Health at the Annual General Meeting to be held on 1 December 2020. Is New 90 Day High Low • Oct 29
New 90-day low: R0.56 The company is down 30% from its price of R0.80 on 31 July 2020. The South African market is down 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 14% over the same period. Announcement • Oct 15
Mary Bomela Resigns as Independent Non-Executive Director of Ascendis Health Limited with Effect from 31 October 2020 Mary Bomela has resigned as an independent non-executive director of the Ascendis Health Limited board of directors with effect from 31 October 2020 and as a result will cease to be the chairman of the social, ethics and transformation committee and a member of the audit and risk committee of the company following that date. Announcement • Oct 04
Ascendis Health Limited Auditor Raises 'Going Concern' Doubt Ascendis Health Limited filed its Annual on Sep 30, 2020 for the period ending Jun 30, 2020. In this report its auditor, PricewaterhouseCoopers LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern. Is New 90 Day High Low • Oct 01
New 90-day low: R0.58 The company is down 33% from its price of R0.87 on 03 July 2020. The South African market is down 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 16% over the same period. Reported Earnings • Sep 30
Full year earnings released - R1.74 loss per share Over the last 12 months the company has reported total losses of R830.8m, with losses narrowing by 83% from the prior year. Total revenue was R6.96b over the last 12 months, up 25% from the prior year. Announcement • Sep 22
Austell Pharmaceuticals Proprietary Limited agreed to acquire Dezzo Trading 392 Proprietary Limited from Ascendis Health Limited (JSE:ASC) for ZAR 80 million. Austell Pharmaceuticals Proprietary Limited agreed to acquire Dezzo Trading 392 Proprietary Limited from Ascendis Health Limited (JSE:ASC) for ZAR 80 million on September 21, 2020. As per terms of transaction, consideration include the initial consideration and deferred consideration which include value of short-dated inventory sold post-closing. The consideration will be paid in cash. Consideration is capped at ZAR 80 million. The transaction is subject to approval by the South African competition authorities, approval of lender consortium of Ascendis Health and other customary closing conditions. Announcement • Jun 22
Ascendis Health Limited(JSE:ASC) dropped from S&P Global BMI Index Ascendis Health Limited(JSE:ASC) dropped from S&P Global BMI Index